Related Experiment Video
Updated: Jul 16, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.8K
Revumenib: First Approval
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|March 12, 2025
Summary
Revumenib is a new oral medication approved for KMT2A-rearranged acute leukaemias. It works by inhibiting the menin protein, promoting cancer cell differentiation and offering a new treatment for patients with specific leukaemias.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Revumenib is a novel oral menin inhibitor targeting KMT2A-rearranged (KMT2Ar) leukaemias.
- The menin-KMT2A interaction drives leukaemogenic transcription in certain leukaemias.
- NPM1-mutated (NPM1m) acute myeloid leukaemia (AML) and solid tumours are also potential indications.
Purpose of the Study:
- To summarize the development milestones of revumenib.
- To highlight the first US approval of revumenib on November 15, 2024.
- To detail its mechanism of action in treating KMT2Ar acute leukaemias.
Main Methods:
- Review of preclinical and clinical data on revumenib development.
- Analysis of revumenib's mechanism of action as a menin inhibitor.
- Summary of regulatory submission and approval process.
Main Results:
- Revumenib demonstrated antileukaemic activity by promoting differentiation.
- The drug targets the menin-KMT2A protein-protein interaction.
- US FDA approval granted for relapsed or refractory (R/R) acute leukaemia with KMT2A translocation in patients aged 1 year and older.
Conclusions:
- Revumenib represents a first-in-class targeted therapy for KMT2Ar leukaemias.
- Its approval signifies a significant advancement in treating specific acute leukaemias.
- Further development may explore its efficacy in NPM1m AML and solid tumours.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).